We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

STAN:LSEStandard Chartered PLC Analysis

Data as of 2026-06-05 - not real-time

£1,943.50

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Standard Chartered is trading just above its 20‑day SMA (1939.66) and comfortably above the 50‑day (1812.12) and 200‑day (1671.98) averages, confirming a bullish market bias. The RSI sits at 53.5, indicating neutral momentum, while the MACD histogram is slightly negative, hinting at a short‑term pull‑back. Volume is on an increasing trend, support sits near 1805.5 and resistance at 2073, providing an upside potential of roughly 8 %. Valuation metrics are attractive: a trailing PE of 12.6 versus the industry average of 16.97, a forward PE of 9.37, and a dividend yield of 2.32 % with a payout ratio under 30 %, suggesting sustainable dividend policy.
Recent earnings beat expectations with a 9 % YoY revenue rise and a 23 % EPS surprise, while JP Morgan has lifted its price target ahead of the May 19 investor day. The bank’s strategic push into regulated crypto via a stake in GSR and a shift toward commission‑based, less capital‑intensive revenues underpin its growth narrative. Analyst consensus remains a “buy,” reinforced by the bank’s strong ROE (~10 %) and solid balance sheet, positioning Standard Chartered for continued upside toward the median target of ≈£2,119.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Price above key moving averages with bullish trend
  • Increasing volume and supportive technical levels
  • Recent earnings beat and upgraded analyst target

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Attractive valuation relative to peers
  • Sustainable dividend yield
  • Strategic diversification into crypto and commission‑based revenues

Long Term

> 3 years
Positive
Model confidence: 9/10

Key Factors

  • Strong ROE and balance‑sheet quality
  • Clear profitability roadmap to 2028
  • Emerging‑market exposure with managed risk profile

Key Metrics & Analysis

Financial Health

Revenue Growth8.60%
Profit Margin26.05%
P/E Ratio12.6
ROE10.11%
ROA0.59%
P/B Ratio1.3
Industry P/E17.0

Technical Analysis

TrendBullish
RSI53.5
Support£1,805.50
Resistance£2,073.00
MA 20£1,939.66
MA 50£1,812.12
MA 200£1,671.98
MACDBearish
VolumeIncreasing
Fear & Greed Index93.38

Valuation

Target Price£2,107.39
Upside/Downside8.43%
GradeUndervalued
TypeBlend
Dividend Yield2.32%

Risk Assessment

Beta0.65
Volatility30.80%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.